与保护性埃博拉病毒抗体结合的粘蛋白域线性表位的结构。
Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.
机构信息
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
出版信息
J Virol. 2012 Mar;86(5):2809-16. doi: 10.1128/JVI.05549-11. Epub 2011 Dec 14.
Abstract
Antibody 14G7 is protective against lethal Ebola virus challenge and recognizes a distinct linear epitope in the prominent mucin-like domain of the Ebola virus glycoprotein GP. The structure of 14G7 in complex with its linear peptide epitope has now been determined to 2.8 Å. The structure shows that this GP sequence forms a tandem β-hairpin structure that binds deeply into a cleft in the antibody-combining site. A key threonine at the apex of one turn is critical for antibody interaction and is conserved among all Ebola viruses. This work provides further insight into the mechanism of protection by antibodies that target the protruding, highly accessible mucin-like domain of Ebola virus and the structural framework for understanding and characterizing candidate immunotherapeutics.
摘要
抗体 14G7 可预防致命的埃博拉病毒感染，能识别埃博拉病毒糖蛋白 GP 中突出的黏液样结构域上的独特线性表位。现在已经确定了 14G7 与其线性肽表位复合物的结构，分辨率为 2.8Å。结构表明，GP 序列形成串联 β-发夹结构，深入结合到抗体结合位点的裂缝中。一个转角顶端的关键苏氨酸对于抗体相互作用至关重要，并且在所有埃博拉病毒中都保守。这项工作进一步深入了解了针对埃博拉病毒突出的高度可及的黏液样结构域的抗体的保护机制，以及理解和表征候选免疫疗法的结构框架。
相似文献
1
Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.
J Virol. 2012 Mar;86(5):2809-16. doi: 10.1128/JVI.05549-11. Epub 2011 Dec 14.
2
Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
Sci Rep. 2014 Nov 6;4:6881. doi: 10.1038/srep06881.
3
Ebola images emerge from the cave.
Cell Host Microbe. 2008 Aug 14;4(2):87-9. doi: 10.1016/j.chom.2008.07.011.
4
Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
J Virol. 2007 Feb;81(4):1821-37. doi: 10.1128/JVI.02098-06. Epub 2006 Dec 6.
5
Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.
mBio. 2016 Feb 23;7(1):e02154-15. doi: 10.1128/mBio.02154-15.
6
Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01845-18. Print 2019 Feb 15.
7
Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.
8
Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography.
J Virol. 2014 Sep;88(18):10958-62. doi: 10.1128/JVI.00870-14. Epub 2014 Jul 9.
9
Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25.
10
[Research progress on ebola virus glycoprotein].
Bing Du Xue Bao. 2013 Mar;29(2):233-7.
引用本文的文献
1
Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies.
Antibodies (Basel). 2025 Mar 5;14(1):22. doi: 10.3390/antib14010022.
2
Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model.
Emerg Microbes Infect. 2024 Dec;13(1):2392651. doi: 10.1080/22221751.2024.2392651. Epub 2024 Aug 26.
3
Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.
J Virol. 2024 Jun 13;98(6):e0052424. doi: 10.1128/jvi.00524-24. Epub 2024 May 17.
4
The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets.
J Infect Dis. 2023 Nov 15;228(Suppl 7):S587-S593. doi: 10.1093/infdis/jiad240.
5
Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination-Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay.
Vaccines (Basel). 2022 Jul 29;10(8):1211. doi: 10.3390/vaccines10081211.
6
Antibodies to combat viral infections: development strategies and progress.
Nat Rev Drug Discov. 2022 Sep;21(9):676-696. doi: 10.1038/s41573-022-00495-3. Epub 2022 Jun 20.
7
Development and Structural Analysis of Antibody Therapeutics for Filoviruses.
Pathogens. 2022 Mar 18;11(3):374. doi: 10.3390/pathogens11030374.
8
Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
Front Immunol. 2022 Jan 10;12:808047. doi: 10.3389/fimmu.2021.808047. eCollection 2021.
9
Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
Front Immunol. 2021 Aug 30;12:721328. doi: 10.3389/fimmu.2021.721328. eCollection 2021.
10
Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects.
Sci Transl Med. 2021 Jul 14;13(602). doi: 10.1126/scitranslmed.abg6128.
本文引用的文献
1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
A shared structural solution for neutralizing ebolaviruses.
Nat Struct Mol Biol. 2011 Nov 20;18(12):1424-7. doi: 10.1038/nsmb.2150.
3
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.
Nature. 2011 Aug 24;477(7364):340-3. doi: 10.1038/nature10348.
4
Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection.
Nature. 2011 Aug 24;477(7364):344-8. doi: 10.1038/nature10380.
5
Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein.
PLoS Pathog. 2010 Sep 9;6(9):e1001098. doi: 10.1371/journal.ppat.1001098.
6
PHENIX: a comprehensive Python-based system for macromolecular structure solution.
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21. doi: 10.1107/S0907444909052925. Epub 2010 Jan 22.
7
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. doi: 10.1107/S0907444909042073. Epub 2009 Dec 21.
8
Glycans on influenza hemagglutinin affect receptor binding and immune response.
Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18137-42. doi: 10.1073/pnas.0909696106. Epub 2009 Oct 12.
9
Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins.
J Virol. 2009 Sep;83(18):9596-601. doi: 10.1128/JVI.00784-09. Epub 2009 Jul 8.
10
HIV-1 and influenza antibodies: seeing antigens in new ways.
Nat Immunol. 2009 Jun;10(6):573-8. doi: 10.1038/ni.1746.
Zotero 插件